These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 32537540)
1. A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab. Boharoon H; Tomlinson J; Limback-Stanic C; Gontsorova A; Martin N; Hatfield E; Meeran K; Nair R; Mendoza N; Levy J; McAdoo S; Pusey C; Wernig F J Endocr Soc; 2020 Jun; 4(6):bvaa048. PubMed ID: 32537540 [TBL] [Abstract][Full Text] [Related]
2. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Gu WJ; Zhang Q; Zhu J; Li J; Wei SH; Mu YM Medicine (Baltimore); 2017 Jun; 96(24):e6934. PubMed ID: 28614220 [TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment for isolated IgG4-related hypophysitis in a teenage female. Bullock DR; Miller BS; Clark HB; Hobday PM Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 30601761 [TBL] [Abstract][Full Text] [Related]
4. A case series of atypical features of patients with biopsy-proven isolated IgG4-related hypophysitis and normal serum IgG4 levels. Yuen KCJ; Moloney KJ; Mercado JU; Rostad S; McCullough BJ; Litvack ZN; Delashaw JB; Mayberg MR Pituitary; 2018 Jun; 21(3):238-246. PubMed ID: 29248982 [TBL] [Abstract][Full Text] [Related]
6. A case of IgG4-related hypophysitis maintained remission of diabetes insipidus for over 3 months after completion of steroid treatment. Kubori M; Fujimoto M; Okauchi Y; Matsuno K; Yamabayashi E; Sakamoto R; Inada S; Iwahashi H Endocrinol Diabetes Metab Case Rep; 2023 Oct; 2023(4):. PubMed ID: 38131878 [TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207 [TBL] [Abstract][Full Text] [Related]
12. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis. Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A Front Immunol; 2020; 11():613. PubMed ID: 32431692 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Campochiaro C; Della-Torre E; Lanzillotta M; Bozzolo E; Baldissera E; Milani R; Arcidiacono PG; Crippa S; Falconi M; Dagna L Eur J Intern Med; 2020 Apr; 74():92-98. PubMed ID: 31901297 [TBL] [Abstract][Full Text] [Related]
14. Deterioration of pituitary function without relapse after steroid therapy for IgG4-related hypophysitis. Nishi N; Takeshima K; Morita S; Iwakura H; Nishi M; Matsuoka T Endocrinol Diabetes Metab Case Rep; 2021 Jul; 2021():. PubMed ID: 34236042 [TBL] [Abstract][Full Text] [Related]
15. Two cases of immunoglobulin G4 (IgG4)-related hypophysitis diagnosed without pituitary biopsy. Ma W; Wang X; Nie M; Fu J; Mao J; Wu X Ther Adv Endocrinol Metab; 2020; 11():2042018820924556. PubMed ID: 32637064 [TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. Ebbo M; Grados A; Samson M; Groh M; Loundou A; Rigolet A; Terrier B; Guillaud C; Carra-Dallière C; Renou F; Pozdzik A; Labauge P; Palat S; Berthelot JM; Pennaforte JL; Wynckel A; Lebas C; Le Gouellec N; Quémeneur T; Dahan K; Carbonnel F; Leroux G; Perlat A; Mathian A; Cacoub P; Hachulla E; Costedoat-Chalumeau N; Harlé JR; Schleinitz N PLoS One; 2017; 12(9):e0183844. PubMed ID: 28915275 [TBL] [Abstract][Full Text] [Related]
17. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Omar D; Chen Y; Cong Y; Dong L Rheumatology (Oxford); 2020 Apr; 59(4):718-726. PubMed ID: 31511884 [TBL] [Abstract][Full Text] [Related]
18. Clinical course of IgG4-related hypophysitis presenting with focal seizure and relapsing lymphocytic hypophysitis. Ngaosuwan K; Trongwongsa T; Shuangshoti S BMC Endocr Disord; 2015 Oct; 15():64. PubMed ID: 26510826 [TBL] [Abstract][Full Text] [Related]